AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
AI can make mistakes. Verify answers against the original sources before relying on them.
dimemorfan 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| opioid receptor antagonists/agonists, morphinan derivates | 900 | 36309-01-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
|
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AKT1,AKT2,AKT3,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,JAK2,JAK3,MAP3K7,MAPK10,MAPK7,MAPKAPK2,MET,NTRK2,PDK2,PDK4,PDPK1,PIM2,PRKDC,SIK2,SIK3,TEK,TGFBR1 | 35 | |||
| kinase-selectivity-class | EIF2AK3,PDK4 | 2 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
None
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Interstitial lung disease | 43.83 | 43.22 | 15 | 352 | 76390 | 90551690 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Interstitial lung disease | 70.69 | 36.71 | 29 | 750 | 139305 | 110449215 |
| Hepatic function abnormal | 50.06 | 36.71 | 20 | 759 | 89275 | 110499245 |
| Malignant neoplasm progression | 42.96 | 36.71 | 22 | 757 | 174545 | 110413975 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | R05DA11 | RESPIRATORY SYSTEM COUGH AND COLD PREPARATIONS COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS Opium alkaloids and derivatives |
| MeSH PA | D000996 | Antitussive Agents |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D019141 | Respiratory System Agents |
| CHEBI has role | CHEBI:51177 | antitussive |
Related Drugs by ATC class:
R05DA Opium alkaloids and derivatives 10 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.55 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Sodium-dependent noradrenaline transporter | Transporter | IC50 | 5.91 | CHEMBL | |||||
| Sigma non-opioid intracellular receptor 1 | Membrane receptor | INHIBITOR | Ki | 6.82 | SCIENTIFIC LITERATURE |
External reference:
| ID | Source |
|---|---|
| D07848 | KEGG_DRUG |
| C0058193 | UMLSCUI |
| CHEBI:135048 | CHEBI |
| CHEMBL2106325 | ChEMBL_ID |
| DB13810 | DRUGBANK_ID |
| C012621 | MESH_SUPPLEMENTAL_RECORD_UI |
| 3037918 | PUBCHEM_CID |
| 3497 | INN_ID |
| 623OAC38YU | UNII |
| 704651005 | SNOMEDCT_US |
| 704652003 | SNOMEDCT_US |
| 36304-84-4 | SECONDARY_CAS_RN |
Pharmaceutical products:
None